Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NUVO gained $0.27 (17%) to $1.90 on Wednesday after it restarted the SONOMA-3 trial of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury